CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Policy governs coverage and medical necessity determination for saturation prostate biopsy (more than 20 cores, transrectal or transperineal template-guided) for diagnosis, staging, and management of prostate cancer for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySaturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2015

Next Review DateN/A

Key ActionDo not submit claims for saturation biopsy for commercial members; the procedure is considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>20definition threshold for saturation biopsy

55706CPT code specific to saturation sampling (listed)

Not medically necessarycoverage stance for commercial products

Noneprior authorization status

11/23/2021

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination

Not medically necessary — all indications

Covered when ALL of the following are met:

Main coverage decision: Saturation biopsy is considered not medically necessary for the diagnosis, staging, and management of prostate cancer because the evidence is insufficient to demonstrate an improvement in net health outcomes.

Applies to Commercial Products; includes initial, repeat, and active surveillance indications as described in the policy.

For Commercial Products, saturation prostate biopsy is not medically necessary for the diagnosis, staging, or management of prostate cancer. The policy states that the evidence is insufficient to demonstrate an improvement in net health outcome, and saturation sampling is therefore not covered for these indications.

The not medically necessary determination is based on the policy conclusion that current evidence does not show saturation biopsy improves clinical outcomes. Specifically, the policy states that evidence is insufficient to determine that saturation sampling results in an improvement in net health outcome, and therefore it is considered not covered for diagnosis, staging, and management of prostate cancer in commercial populations.

Coding and Definitions

Covered/Listed CPT CodesCPT

55706

Biopsies, prostate, needle, transperineal, stereotactic template saturation sampling, including imaging guidance

Codes not specific to saturation (do not file for saturation claims)mixedNot Covered

55700	Biopsy, prostate; needle, transrectal, single or multiple, any approach (not specific to saturation)
G0416	Prostate biopsy, transrectal or transperineal, systematic sampling (not specific to saturation)

inv-06: Saturation core count threshold — >20 cores

Saturation core-count threshold>20 cores (procedure defined as more than 20 prostate cores)

Typical purposeTo improve sampling of anterior zones that may be undersampled by standard peripheral strategies

ApproachesMay be performed transrectally or transperineally (often stereotactic template-guided)

Provider Requirements and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is not required for this service.

Documentation Required

Benefit and Member Documentation

Refer to the member's Benefit Booklet, Evidence of Coverage or Subscriber Agreement to determine covered benefits and any applicable limitations or exclusions.

Denial Risk

Denial triggers / Coding Guidance

Saturation biopsy (CPT 55706) is considered not medically necessary for Commercial Products. Claims for saturation biopsy should not be reported with CPT 55700 or G0416 when performing saturation sampling. For Medicare Advantage plans, CPT 55706 is not covered.

Background and Rationale

Saturation biopsy refers to taking substantially more cores than standard protocols—generally defined as more than 20 cores—to sample regions of the prostate (including anterior zones) that may be under-sampled by routine or extended approaches. It can be performed via a transrectal route or via a transperineal, stereotactic template-guided approach, the latter often used with imaging guidance and under anesthesia for comprehensive mapping. Although saturation sampling increases the number of tissue cores obtained, the policy notes that available evidence has not demonstrated improved patient-level outcomes (for example, survival or progression) compared with standard or extended biopsy strategies, which is why saturation biopsy is not covered for diagnosis, staging, or management of prostate cancer.

Definitions

inv-12: Saturation biopsy definition — generally >20 cores

Definition (saturation biopsy)Generally more than 20 cores taken from the prostate

Sampling benefitImproves sampling of anterior zones that may be missed by standard peripheral-zone strategies

Typical techniqueCan be performed transrectally or transperineally; transperineal often uses stereotactic template guidance under anesthesia

inv-13: Extended biopsy definition — 10 to 14 cores (commonly 12-14)

Extended biopsy core rangeGenerally 10 to 14 cores (commonly 12–14)

PurposeInitial biopsy strategy to sample lateral peripheral zones and lateral horn to increase cancer detection versus sextant 6-core approach